Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or recurrent non-small cell lung cancer (NSCLC): PrECOG PrE0501—Update on maintenance treatment, progression-free survival (PFS), and overall survival (OS).
J. Aisner
Research Funding - Cancer Institute of New Jersey
J. Manola
No relevant relationships to disclose
S. R. Dakhil
No relevant relationships to disclose
P. J. Stella
No relevant relationships to disclose
J. H. Schiller
Consultant or Advisory Role - AstraZeneca
Research Funding - AstraZeneca